Imunon’s OVATION 2 Survival Improves to 14.7 Months, Phase 3 Funding Plans Underway
Imunon reported OVATION 2 median overall survival rose from 11.1 to 14.7 months and says OVATION 3 is enrolling ahead of schedule with interim analysis due one year after full enrollment. With $8.8 million cash runway into H2 2026, Imunon will seek financing or partnerships to complete Phase 3 trial.
1. Trial Milestones and Interim Plans
Imunon’s Phase 3 OVATION 3 trial is enrolling ahead of schedule, with clinical sites and investigators expressing high interest. The first interim analysis is planned approximately one year after full patient enrollment, incorporating early efficacy stopping rules that could accelerate a Biologics License Application filing.
2. Efficacy Data from OVATION 2
The final analysis of the OVATION 2 study showed median overall survival increased from 11.1 months to 14.7 months in patients receiving Imunon-001, reinforcing the design and objectives of the ongoing Phase 3 trial in the PARP inhibitor population.
3. Financial Position and Partnership Strategy
As of the Q4 call, Imunon holds $8.8 million in cash, extending its operating runway into the second half of 2026. Management plans to pursue additional financing—both dilutive and non-dilutive—and strategic partnerships to fully fund OVATION 3 and support expansion of its TheraPlas technology platform.